Skip to main content
Industry News
Novartis, Artios partner for cancer therapies

A global research collaboration has been formalized between Novartis and Artios Pharma to target next-generation DNA damage response as Novartis builds up its radioligand therapies portfolio. Artios is eligible to receive $20 million as an upfront payment and up to $1.3 billion in milestone payments and sales aside from royalty payments.

Full Story: